119 related articles for article (PubMed ID: 15197326)
1. The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy AR; Bristow RG
Cancer Metastasis Rev; 2004; 23(3-4):237-57. PubMed ID: 15197326
[TBL] [Abstract][Full Text] [Related]
2. The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation.
Rosen EM; Fan S; Rockwell S; Goldberg ID
Cancer Invest; 1999; 17(1):56-72. PubMed ID: 10999050
[TBL] [Abstract][Full Text] [Related]
3. Role of cell cycle in mediating sensitivity to radiotherapy.
Pawlik TM; Keyomarsi K
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):928-42. PubMed ID: 15234026
[TBL] [Abstract][Full Text] [Related]
4. Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells.
Böhnke A; Westphal F; Schmidt A; El-Awady RA; Dahm-Daphi J
Int J Radiat Biol; 2004 Jan; 80(1):53-63. PubMed ID: 14761850
[TBL] [Abstract][Full Text] [Related]
5. [Cell cycle regulation after exposure to ionizing radiation].
Teyssier F; Bay JO; Dionet C; Verrelle P
Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
[TBL] [Abstract][Full Text] [Related]
6. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
7. The role of p53 in chemosensitivity and radiosensitivity.
El-Deiry WS
Oncogene; 2003 Oct; 22(47):7486-95. PubMed ID: 14576853
[TBL] [Abstract][Full Text] [Related]
8. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
Satyamoorthy K; Chehab NH; Waterman MJ; Lien MC; El-Deiry WS; Herlyn M; Halazonetis TD
Cell Growth Differ; 2000 Sep; 11(9):467-74. PubMed ID: 11007451
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
10. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation.
Scott SL; Earle JD; Gumerlock PH
Cancer Res; 2003 Nov; 63(21):7190-6. PubMed ID: 14612513
[TBL] [Abstract][Full Text] [Related]
11. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.
Bristow RG; Benchimol S; Hill RP
Radiother Oncol; 1996 Sep; 40(3):197-223. PubMed ID: 8940748
[TBL] [Abstract][Full Text] [Related]
12. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
Sun Y; Tran BN; Worley LA; Delston RB; Harbour JW
Invest Ophthalmol Vis Sci; 2005 May; 46(5):1561-4. PubMed ID: 15851551
[TBL] [Abstract][Full Text] [Related]
14. DNA damage-induced cell death by apoptosis.
Roos WP; Kaina B
Trends Mol Med; 2006 Sep; 12(9):440-50. PubMed ID: 16899408
[TBL] [Abstract][Full Text] [Related]
15. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.
Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
Oncogene; 2001 Sep; 20(39):5503-10. PubMed ID: 11571648
[TBL] [Abstract][Full Text] [Related]
16. Targeting p53 for enhanced radio- and chemo-sensitivity.
Lu C; El-Deiry WS
Apoptosis; 2009 Apr; 14(4):597-606. PubMed ID: 19259822
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
18. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
Jones GG; Reaper PM; Pettitt AR; Sherrington PD
Oncogene; 2004 Mar; 23(10):1911-21. PubMed ID: 14755251
[TBL] [Abstract][Full Text] [Related]
19. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
[TBL] [Abstract][Full Text] [Related]
20. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
